Quinoline derivative
US10208022B2 · kind B2 · utility
1Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 2018 |
| Grant date | Feb 19, 2019 |
| Priority date | — |
| Expiry date | May 10, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.